Published in
American Society of Hematology, Blood, p. blood-2018-05-852798
DOI: 10.1182/blood-2018-05-852798
Links
Tools
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Journal article published in 2018 by
Emma C. Fink 
,
Marie McConkey,
Dylan N. Adams,
Saurav D. Haldar,
James A. Kennedy,
Andrew A. Guirguis ,
Namrata D. Udeshi,
D. R. Mani,
Michelle Chen,
Brian Liddicoat,
Tanya Svinkina,
Andrew T. Nguyen,
Steven A. Carr,
Benjamin L. Ebert
,
Marie McConkey,
Dylan N. Adams,
Saurav D. Haldar,
James A. Kennedy,
Andrew A. Guirguis ,
Namrata D. Udeshi,
D. R. Mani,
Michelle Chen,
Brian Liddicoat,
Tanya Svinkina,
Andrew T. Nguyen,
Steven A. Carr,
Benjamin L. Ebert
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points Crbn I391V mice degrade known thalidomide derivative targets and recapitulate thalidomide-induced cytopenias and teratogenicity. Degradation of Ck1α is sufficient to explain the in vivo therapeutic window of lenalidomide in del(5q) myelodysplastic syndrome.